J&J declares a historic success as Invokana comes through in PhIII chronic kidney disease trial

J&J has scored positive data from its Phase III chronic kidney disease study of the SGLT2 diabetes drug Invokana, possibly opening the door to a comeback after watching sales revenue dwindle in the face of a safety alert.